Intervention Protocol

Pharmacological treatment for muscle weakness and wasting in myotonic dystrophy

  1. Chris Turner1,*,
  2. David Hilton-Jones2

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 17 FEB 2010

DOI: 10.1002/14651858.CD008377

How to Cite

Turner C, Hilton-Jones D. Pharmacological treatment for muscle weakness and wasting in myotonic dystrophy (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No.: CD008377. DOI: 10.1002/14651858.CD008377.

Author Information

  1. 1

    National Hospital for Neurology and Neurosurgery, MRC Centre for Neuromuscular Disease, London, UK

  2. 2

    John Radcliffe Hospital, Department of Clinical Neurology, Oxford, UK

*Chris Turner, MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK. chris.turner@uclh.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 17 FEB 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To prepare a systematic review of randomised controlled trials (RCTs) of pharmacological treatment for DM1 and DM2. If RCTs do not exist, the need for RCTs and the most appropriate trial designs and outcomes will be considered in the discussion in the context of non-randomised studies.